PTPN12 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Kumanon H (SCHEMBL150578)	1.00	4/20
SCHEMBL1904243	0.63	4/20
SCHEMBL1904245	0.63	4/20
SCHEMBL1904246	0.63	4/20
SCHEMBL651434	0.54	4/20
SCHEMBL651435	0.54	4/20
SCHEMBL650337	0.44	4/20
SCHEMBL650338	0.44	4/20
SCHEMBL2397608	1.00	3/20
SCHEMBL2398377	1.00	3/20
SCHEMBL783008	0.53	3/20
SCHEMBL801547	0.53	3/20
SCHEMBL1650266	0.45	3/20
Ethylene (SCHEMBL707063)	0.38	3/20
SCHEMBL652210	0.37	3/20
SCHEMBL2397611	0.82	2/20
SCHEMBL253019	0.61	2/20
SCHEMBL250646	0.56	2/20
SCHEMBL1421364	0.53	2/20
SCHEMBL1421366	0.53	2/20

Clinical trials — most relevant to PTPN12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC	PHASE2/PHASE3	NOT_YET_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Quantification of GADD34 Expression in RA	nan	COMPLETED
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN12 binder may also engage these)

Protein	Name	Similarity
P46200	—	0.993	P46200 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
P35831	—	0.993	P35831 →
A6QP06	—	0.992	A6QP06 →
Q92539	—	0.992	Q92539 →
Q86TC9	—	0.992	Q86TC9 →
PTPN22	Tyrosine-protein phosphatase non-receptor type 22	0.992	landscape →
Q2PFD7	—	0.991	Q2PFD7 →
Q99PI5	—	0.991	Q99PI5 →
Q66HD5	—	0.991	Q66HD5 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.991	landscape →
Q0WPH8	—	0.991	Q0WPH8 →
A2A3K4	—	0.990	A2A3K4 →
Q6NN85	—	0.990	Q6NN85 →
B3NLX1	—	0.990	B3NLX1 →
Q09354	—	0.990	Q09354 →
Q811D2	—	0.990	Q811D2 →
P70047	—	0.990	P70047 →
P70284	—	0.990	P70284 →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.990	landscape →
Q90ZS6	—	0.989	Q90ZS6 →
B4P6W7	—	0.989	B4P6W7 →
Q8C0I4	—	0.989	Q8C0I4 →
Q9D2H8	—	0.989	Q9D2H8 →
Q1LXZ9	—	0.989	Q1LXZ9 →
Q32KD2	—	0.989	Q32KD2 →
NEDD4	E3 ubiquitin-protein ligase NEDD4	0.989	landscape →
A0A2K1J5A5	—	0.989	A0A2K1J5A5 →
PEAK1	Inactive tyrosine-protein kinase PEAK1	0.989	landscape →
F4JZ68	—	0.989	F4JZ68 →